《诺华公司Novartis（NVS）2025年第一季度影响和可持续发展更新报告「NYSE」（英文版）（11页）.pdf》由会员分享，可在线阅读，更多相关《诺华公司Novartis（NVS）2025年第一季度影响和可持续发展更新报告「NYSE」（英文版）（11页）.pdf（11页珍藏版）》请在三个皮匠报告上搜索。

1、WelcomeContentClick below to navigate through the documentTop 10 questions from shareholders2025 AGM outcomesMeet Korab Zuka Edition no.21 Q1 2025 Impact and Sustainability Update to investors For any questions and comments,please reach out to:Sloan SimpsonGlobal Head of Investor R+1 862 345 4440Mar

2、ia Victoria CuevasInvestor Relations Executive Director&ESG H+41 79 586 52 85Dear investors and analysts,Our Q1 update shares key highlights from our 2025 AGM and includes a short Q&A with Korab Zuka,the recently appointed Global Head of SociaI Impact&Chief Sustainability Officer at Novartis,whom yo

3、u will hopefully have the opportunity to engage with over the coming months.As always,we also include top questions from shareholders during Q1 and our responses.We thank you for your continued engagement.Q1 impact and sustainability update|2ContentClick below to navigate through the documentWelcome

4、Top 10 questions from shareholders2025 AGM outcomesMeet Korab Zuka 1.Based on the Novartis SIX Swiss Exchange closing share price of CHF 99.47 on March 6,2025.2.As of December 31,2024.2025 AGM outcomesBoard elections,including new Board Chair Shareholders elected Dr.Giovanni Caforio as a new member

5、of the Board of Directors and Board Chair with more than 98%support.Giovanni has had an international career in the healthcare industry spanning more than 35 years,most recently as the Chairman and CEO of Bristol Myers Squibb(BMS).In addition,shareholders elected Dr.Elizabeth(Beth)McNally,with more

6、than 99%support,as a new member of the Board of Directors.Beth is a human geneticist and cardiologist with extensive experience as a physician,scientist and professor at leading academic institutions in the US.All other members of the Board of Directors,who were standing for re-election,were elected